Document text
Principal Investigator: Nerea Zabaleta
Organization: SCHEPENS EYE RESEARCH INSTITUTE
Fiscal Year: 2024
Award: $668,569
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY/ABSTRACT
Broadening the spectrum of vaccine platforms that confer protective, durable and broad immunogenicity is
important for pandemic preparedness. Here, we aim to create essential preclinical data to characterize a novel
genetic vaccine platform called PARVAX to increase its clinical acceptance. Our previous studies show that a
single dose of PARVAX candidates for COVID-19 elicits sustained humoral immunity, near-sterilizing upper
and lower airway protection from a SARS-CoV-2 challenge, and potent and durable cellular responses. These
qualities combined with established commercial and low-cost manufacturing processes, make this platform
imminently feasible, scalable and affordable for vaccine applications. In this proposal, we will investigate the
mechanism behind the potency and durability of PARVAX, which we hypothesize is correlated with antigen
expression kinetics (Aim 1). We also use rational engineering approaches to enhance the potency of the
PARVAX platform, which will enhance safety and applicability for other pathogens (Aim 2). Finally, we propose
to generate proof of the potency of PARVAX as a vaccine platform beyond COVID-19 by exploring the serum
and mucosal immunity and protection from influenza viruses in two preclinical models of influenza infection
(Aim 3). The proposed work is highly relevant for pandemic preparedness, since it will enable the rapid design
of new and preclinically derisked PARVAX candidates for existing and future pathogens, and has the potential
to provide clarity on the means to improve the durability, breadth and mucosal immunity of other platforms.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Adeno-Associated Viruses><Adenoviridae><Adenoviruses><Affinity><Antibodies><Antibody Response><Antigen-Antibody Complex><Antigen-Presenting Cells><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Blood Serum><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 antigen><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 virus><COVID-19 years><COVID19 virus><CV-19><Capsid><Cavia><Cell Body><Cell Maturation><Cell-Mediated Lympholytic Cells><Cells><Characteristics><Clinical><CoV-2><CoV2><Cold Chains><Complex><Coronavirus Infectious Disease 2019><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><DNA><DNA Therapy><Data><Dendritic Cells><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Deposit><Deposition><Dose><Engineering><Enhancement Technology><Exhibits><Future><Gene Transfer><Gene Transfer Clinical><Genes><Genetic Intervention><Genome><Germinal Center><Guinea Pigs><Guinea Pigs Mammals><H1N1><H1N1 Virus><Human><Humoral Immunities><Immune><Immune Cell Activation><Immune Complex><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Infection><Influenza A Virus, H1N1 Subtype><Influenza Virus><Innate Immunity><Intramuscular><Kinetics><Memory><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Mucosa><Mucosal Immunity><Mucosal Tissue><Mucous Membrane><Murine><Mus><Native Immunity><Natural Immunity><Non-Specific Immunity><Nonspecific Immunity><Osmosis><Pathway interactions><Pattern><Peptides><Pre-Clinical Model><Preclinical Models><Preventative vaccine><Prevention><Preventive vaccine><Prophylactic vaccine><Pump><RNA vaccine><RNA-based vaccine><Recombinants><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antigen><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Serotyping><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Specificity><Structure of germinal center of lymph node><Surface><T cell response><TLR9 gene><TLR9 protein><TLR9 receptor><Technology><Time><Transgenes><Transmission><Tropism><Vaccines><Veiled Cells><Work><Wuhan coronavirus><accessory cell><adaptive immunity><adeno associated virus group><antibody-based immunity><cell transduction><cellular transduction><clinical relevance><clinically relevant><coronavirus disease 2019><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><cost><design><designing><efficacy study><efficacy testing><epidemic concern><epidemic potential><epidemic risk><epidemic threat><fabrication cost><flu infection><flu virus infection><future epidemic><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetic vaccine><genomic therapy><hCoV19><immune activation><immunogen><immunogenicity><improved><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza infection><influenza virus infection><influenzavirus><insight><killer T cell><mRNA><mRNA vaccine><mRNA-based vaccine><manufacturing cost><manufacturing process><nCoV2><new vaccines><next epidemic><next generation vaccines><non-human primate><nonhuman primate><novel><novel vaccines><outcome following vaccination><outcome following vaccine><pandemic><pandemic disease><pandemic disease preparedness><pandemic pathogen><pandemic planning><pandemic preparedness><pandemic readiness><pathogen><pathway><pre-clinical><preclinical><promoter><promotor><prototype><response><result following vaccination><result following vaccine><safety study><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><tech development><technology development><thermolability><thermostability><toll-like receptor 9><transduced cells><transgene><transmission process><vaccination outcome><vaccination result><vaccine candidate><vaccine efficacy><vaccine outcome><vaccine platform><vaccine result><vector>